WO2025237234 - ANTI-CDH3 ANTIBODIES AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2025/237234
Publication Date
20.11.2025
International Application No.
PCT/CN2025/094257
International Filing Date
12.05.2025
Title **
[English]
ANTI-CDH3 ANTIBODIES AND USES THEREOF
[French]
ANTICORPS ANTI-CDH3 ET LEURS UTILISATIONS
Applicants **
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Inventors
HAO, Kunying
SHANG, Chengzhang
YANG, Yi
SHEN, Yuelei
Priority Data
PCT/CN2024/092814
13.05.2024
CN
PCT/CN2024/127352
25.10.2024
CN
PCT/CN2025/072409
15.01.2025
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2962 | |
| EPO | Filing, Examination, Granting | 26407 | |
| Japan | Filing, Examination, Granting | 2954 | |
| South Korea | Filing, Examination, Granting | 3930 | |
| USA | Filing, Examination, Granting | 14340 |
Total:
50,593
Contact Us
Abstract[English]
Anti-CDH3 antibodies or antigen binding fragments thereof, and antibody drug conjugates are disclosed.[French]
Sont divulgués des anticorps anti-CDH3 ou des fragments de liaison à l'antigène de ceux-ci, et des conjugués anticorps-médicament.